Novel approaches to pulmonary fibrosis

Clin Med (Lond). 2014 Dec:14 Suppl 6:s45-9. doi: 10.7861/clinmedicine.14-6-s45.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a poor prognosis and few treatment options. However, recent research into this condition has led to considerable insights into the pathophysiology of the disease, resulting in the identification of potential biomarkers to aid diagnosis and stratification of patients and the development of novel therapies. In this review we will discuss the recent developments in this field and review how this knowledge has been translated into clinical trials and a paradigm shift in our approach to patients with IPF.

Keywords: Idiopathic pulmonary fibrosis; biomarkers; nintedanib; pirfenidone.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Humans
  • Idiopathic Pulmonary Fibrosis* / diagnosis
  • Idiopathic Pulmonary Fibrosis* / physiopathology
  • Idiopathic Pulmonary Fibrosis* / therapy
  • Indoles
  • Pyridones

Substances

  • Biomarkers
  • Indoles
  • Pyridones
  • pirfenidone
  • nintedanib